Drugs Made In America Acquisition Corp. (DMAA): Entry into a Material Definitive Agreement
Drugs Made In America Acquisition Corp. (DMAA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0002028614 0002028614 2026-07-14 2026-07-14 0002028614 DMAA:UnitsEachConsistingOfOneOrdinaryShareParValue0.0001PerShareAndOneRightToReceiveOneeighth18OfOrdinaryShareMember 2026-07-14 2026-07-14 0002028614 DMAA:OrdinarySharesMember 2026-07-14 2026-07-14 0002028614 us-gaap:Ri
How this was made
The 30-second read
Why it matters
Amendment No. 3 changes sponsor/founder share treatment (forfeiture and earnout vesting thresholds), modifies rights handling (tender/exchange/consent with a $0.25 to $0.35 per right range), and restates minimum cash targets and floors, all of which can affect deal economics and closing certainty.
Market read
Traders should reassess DMAA’s merger economics and redemption/rights dynamics after the sponsor treatment, rights settlement, and minimum cash floors were updated in the SEC filing.
What to watch
Watch for how the rights tender/exchange option and the $30M target/$15M floor cash provisions affect redemption risk and the probability of closing, plus any later disclosure tied to the potential Amendment No. 4 negotiations.
Background
DMAA previously announced a definitive merger agreement with PAGC, later amended twice, and now filed a third amendment approved by both boards on July 14, 2026.
Ticker impact
DMAA disclosed Amendment No. 3 to its merger agreement, including founder share forfeiture, rights tender terms, and revised minimum cash floors.
Near-term volatility likely around deal mechanics and any investor reaction to founder forfeiture and rights settlement pricing.
The filing is a primary SEC disclosure of amended merger terms, but it does not provide a new valuation headline or definitive closing date, so impact is likely incremental rather than a full repricing catalyst.
Market effects
SPAC merger structures and rights settlement mechanics may influence how investors price similar AI/analytics SPAC combinations.
Primarily impacts US-listed SPAC trading sentiment on Nasdaq, with limited direct regional spillover.
Low global relevance; the update is deal-specific to DMAA and its target PAGC.
Counterpoint
The amendment may be largely procedural, with economics already anticipated from prior disclosures, limiting incremental price impact.
Key entities
- SPACDrugs Made In America Acquisition Corp.
Nasdaq-listed Cayman Islands exempted company filing the 8-K and amending its merger agreement.
- Target companyPower Analytics Global Corp
Delaware corporation engaged in AI, advanced analytics, and quantum-resistant security solutions, the merger counterparty.
